Literature DB >> 25602521

RB loss contributes to aggressive tumor phenotypes in MYC-driven triple negative breast cancer.

Erik S Knudsen1, A Kathleen McClendon, Jorge Franco, Adam Ertel, Paolo Fortina, Agnieszka K Witkiewicz.   

Abstract

Triple negative breast cancer (TNBC) is characterized by multiple genetic events occurring in concert to drive pathogenic features of the disease. Here we interrogated the coordinate impact of p53, RB, and MYC in a genetic model of TNBC, in parallel with the analysis of clinical specimens. Primary mouse mammary epithelial cells (mMEC) with defined genetic features were used to delineate the combined action of RB and/or p53 in the genesis of TNBC. In this context, the deletion of either RB or p53 alone and in combination increased the proliferation of mMEC; however, the cells did not have the capacity to invade in matrigel. Gene expression profiling revealed that loss of each tumor suppressor has effects related to proliferation, but RB loss in particular leads to alterations in gene expression associated with the epithelial-to-mesenchymal transition. The overexpression of MYC in combination with p53 loss or combined RB/p53 loss drove rapid cell growth. While the effects of MYC overexpression had a dominant impact on gene expression, loss of RB further enhanced the deregulation of a gene expression signature associated with invasion. Specific RB loss lead to enhanced invasion in boyden chambers assays and gave rise to tumors with minimal epithelial characteristics relative to RB-proficient models. Therapeutic screening revealed that RB-deficient cells were particularly resistant to agents targeting PI3K and MEK pathway. Consistent with the aggressive behavior of the preclinical models of MYC overexpression and RB loss, human TNBC tumors that express high levels of MYC and are devoid of RB have a particularly poor outcome. Together these results underscore the potency of tumor suppressor pathways in specifying the biology of breast cancer. Further, they demonstrate that MYC overexpression in concert with RB can promote a particularly aggressive form of TNBC.

Entities:  

Keywords:  EMT; MYC; RB tumor suppressor; Triple negative breast cancer; basal-like breast cancer; biomarkers; cell cycle; p53; targeted therapy

Mesh:

Substances:

Year:  2015        PMID: 25602521      PMCID: PMC4353068          DOI: 10.4161/15384101.2014.967118

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  48 in total

1.  Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies.

Authors:  Brian D Lehmann; Joshua A Bauer; Xi Chen; Melinda E Sanders; A Bapsi Chakravarthy; Yu Shyr; Jennifer A Pietenpol
Journal:  J Clin Invest       Date:  2011-07       Impact factor: 14.808

Review 2.  Triple-negative breast cancer.

Authors:  William D Foulkes; Ian E Smith; Jorge S Reis-Filho
Journal:  N Engl J Med       Date:  2010-11-11       Impact factor: 91.245

3.  Rb deletion in mouse mammary progenitors induces luminal-B or basal-like/EMT tumor subtypes depending on p53 status.

Authors:  Zhe Jiang; Tao Deng; Robert Jones; Huiqin Li; Jason I Herschkowitz; Jeff C Liu; Victor J Weigman; Ming-Sound Tsao; Timothy F Lane; Charles M Perou; Eldad Zacksenhaus
Journal:  J Clin Invest       Date:  2010-08-02       Impact factor: 14.808

4.  Transcriptional amplification in tumor cells with elevated c-Myc.

Authors:  Charles Y Lin; Jakob Lovén; Peter B Rahl; Ronald M Paranal; Christopher B Burge; James E Bradner; Tong Ihn Lee; Richard A Young
Journal:  Cell       Date:  2012-09-28       Impact factor: 41.582

5.  Prediction and genetic demonstration of a role for activator E2Fs in Myc-induced tumors.

Authors:  Kenichiro Fujiwara; Inez Yuwanita; Daniel P Hollern; Eran R Andrechek
Journal:  Cancer Res       Date:  2011-01-18       Impact factor: 12.701

Review 6.  Tailoring to RB: tumour suppressor status and therapeutic response.

Authors:  Erik S Knudsen; Karen E Knudsen
Journal:  Nat Rev Cancer       Date:  2008-09       Impact factor: 60.716

7.  p21CIP1 attenuates Ras- and c-Myc-dependent breast tumor epithelial mesenchymal transition and cancer stem cell-like gene expression in vivo.

Authors:  Manran Liu; Mathew C Casimiro; Chenguang Wang; L Andrew Shirley; Xuanmao Jiao; Sanjay Katiyar; Xiaoming Ju; Zhiping Li; Zuoren Yu; Jie Zhou; Michael Johnson; Paolo Fortina; Terry Hyslop; Jolene J Windle; Richard G Pestell
Journal:  Proc Natl Acad Sci U S A       Date:  2009-10-26       Impact factor: 11.205

Review 8.  The role of hormonal therapy in the management of hormonal-receptor-positive breast cancer with co-expression of HER2.

Authors:  Aleix Prat; José Baselga
Journal:  Nat Clin Pract Oncol       Date:  2008-07-08

9.  Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone.

Authors:  Nathalie A Johnson; Graham W Slack; Kerry J Savage; Joseph M Connors; Susana Ben-Neriah; Sanja Rogic; David W Scott; King L Tan; Christian Steidl; Laurie H Sehn; Wing C Chan; Javeed Iqbal; Paul N Meyer; Georg Lenz; George Wright; Lisa M Rimsza; Carlo Valentino; Patrick Brunhoeber; Thomas M Grogan; Rita M Braziel; James R Cook; Raymond R Tubbs; Dennis D Weisenburger; Elias Campo; Andreas Rosenwald; German Ott; Jan Delabie; Christina Holcroft; Elaine S Jaffe; Louis M Staudt; Randy D Gascoyne
Journal:  J Clin Oncol       Date:  2012-07-30       Impact factor: 44.544

10.  E-cadherin repression contributes to c-Myc-induced epithelial cell transformation.

Authors:  V H Cowling; M D Cole
Journal:  Oncogene       Date:  2006-12-04       Impact factor: 9.867

View more
  20 in total

1.  RB Loss Promotes Prostate Cancer Metastasis.

Authors:  Chellappagounder Thangavel; Ettickan Boopathi; Yi Liu; Alex Haber; Adam Ertel; Anshul Bhardwaj; Sankar Addya; Noelle Williams; Stephen J Ciment; Paolo Cotzia; Jeffry L Dean; Adam Snook; Chris McNair; Matt Price; James R Hernandez; Shuang G Zhao; Ruth Birbe; James B McCarthy; Eva A Turley; Kenneth J Pienta; Felix Y Feng; Adam P Dicker; Karen E Knudsen; Robert B Den
Journal:  Cancer Res       Date:  2016-12-06       Impact factor: 12.701

Review 2.  Decoding the link between WWOX and p53 in aggressive breast cancer.

Authors:  Suhaib K Abdeen; Rami I Aqeilan
Journal:  Cell Cycle       Date:  2019-05-16       Impact factor: 4.534

3.  RB1 deficiency in triple-negative breast cancer induces mitochondrial protein translation.

Authors:  Robert A Jones; Tyler J Robinson; Jeff C Liu; Mariusz Shrestha; Veronique Voisin; YoungJun Ju; Philip E D Chung; Giovanna Pellecchia; Victoria L Fell; SooIn Bae; Lakshmi Muthuswamy; Alessandro Datti; Sean E Egan; Zhe Jiang; Gustavo Leone; Gary D Bader; Aaron Schimmer; Eldad Zacksenhaus
Journal:  J Clin Invest       Date:  2016-08-29       Impact factor: 14.808

4.  Polyploid giant cancer cells, stemness and epithelial-mesenchymal plasticity elicited by human cytomegalovirus.

Authors:  Zeina Nehme; Sébastien Pasquereau; Sandy Haidar Ahmad; Alain Coaquette; Chloé Molimard; Franck Monnien; Marie-Paule Algros; Olivier Adotevi; Mona Diab Assaf; Jean-Paul Feugeas; Georges Herbein
Journal:  Oncogene       Date:  2021-03-25       Impact factor: 9.867

Review 5.  Dual function of MDM2 and MDMX toward the tumor suppressors p53 and RB.

Authors:  Jesús Hernández-Monge; Adriana Berenice Rousset-Roman; Ixaura Medina-Medina; Vanesa Olivares-Illana
Journal:  Genes Cancer       Date:  2016-09

6.  Targeting EphA2 impairs cell cycle progression and growth of basal-like/triple-negative breast cancers.

Authors:  W Song; Y Hwang; V M Youngblood; R S Cook; J M Balko; J Chen; D M Brantley-Sieders
Journal:  Oncogene       Date:  2017-06-05       Impact factor: 9.867

7.  MYC overexpression with its prognostic and clinicopathological significance in breast cancer.

Authors:  Jingkun Qu; Xixi Zhao; Jizhao Wang; Xu Liu; Yan Yan; Lin Liu; Hui Cai; Hangying Qu; Ning Lu; Yuchen Sun; Feidi Wang; Jiansheng Wang; Jia Zhang
Journal:  Oncotarget       Date:  2017-10-05

8.  Widespread Exaptation of L1 Transposons for Transcription Factor Binding in Breast Cancer.

Authors:  Jiayue-Clara Jiang; Joseph A Rothnagel; Kyle R Upton
Journal:  Int J Mol Sci       Date:  2021-05-25       Impact factor: 5.923

9.  Circuits of cancer drivers revealed by convergent misregulation of transcription factor targets across tumor types.

Authors:  Abel Gonzalez-Perez
Journal:  Genome Med       Date:  2016-01-20       Impact factor: 11.117

10.  MYC functions are specific in biological subtypes of breast cancer and confers resistance to endocrine therapy in luminal tumours.

Authors:  Andrew R Green; Mohammed A Aleskandarany; Devika Agarwal; Somaia Elsheikh; Christopher C Nolan; Maria Diez-Rodriguez; R Douglas Macmillan; Graham R Ball; Carlos Caldas; Srinivasan Madhusudan; Ian O Ellis; Emad A Rakha
Journal:  Br J Cancer       Date:  2016-03-08       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.